L-DOPA treatment for Parkinson's can lead to addictive disorders in about 25% of patients because it binds dopamine receptors in the reward pathway, with risk being dose-dependent. — Whalespan
L-DOPA treatment for Parkinson's can lead to addictive disorders in about 25% of patients because it binds dopamine receptors in the reward pathway, with risk being dose-dependent.
⚠ High risk
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
◐PARTIALLYSUPPORTED
⚠
High-risk intervention — consult a physician before acting.Drug-drug interactions, dose-dependence, and screening contraindications apply.
“unfortunately uh lopa transformed to dopamine also binds dopamine receptors in the reward pathway which is why about a quarter of folks with Parkinson's who get treated with elopa end up with uh addictive disorders that are usually uh reversible when you stop the elopa and tend to be um dose dependent so the more lopa the more likely the sex addiction shopping addiction or whatever the compulsive Behavior”